
Design novel, synthesizable drug candidates meeting TPP constraints efficiently.
What is Iktos?
Iktos: Design novel, synthesizable drug candidates meeting TPP constraints efficiently. Zekai's independent review scores it 6.8 out of 10. Best for accelerating early-stage drug discovery with generative AI.
Zekai Verdict
- What is it?
- Iktos is a generative AI platform designed to accelerate early-stage drug discovery.
- Best for
- Medicinal chemists and computational chemists engaged in early-stage drug discovery. The platform's ability to generate…
- Price
- Pricing on request
- Zekai Score
- 6.8/10
For pharmaceutical and biotech professionals, Iktos is a leading AI for early-stage drug discovery. Its generative AI platform goes beyond virtual screening by creating novel, synthesizable small molecules from the ground up. This allows medicinal chemists to rapidly design high-quality lead candidates optimized against complex Target Product Profiles, significantly accelerating the hit-to-lead process.
See Iktos in action
Try it with these prompts
Copy any prompt and paste it directly into the tool.
Design novel drug molecules with Makya's generative AI. Focus on synthetic accessibility and multi-parametric optimization against project objectives. Specify 3D constraints if applicable.
Plan efficient synthesis routes for a target compound using Spaya. Identify feasible pathways from commercially available starting materials, optimizing for your specific needs and robotic systems.
Automate the complete synthetic process from workflow management to execution using Iktos Robotics. Generate high-throughput data for iterative DMTA cycles to accelerate candidate identification.
Prompts for Pharma
Paid remote AI jobs for people who use tools like Iktos
AI companies pay experts by the hour to test and improve AI. Remote and flexible. These roles are open now.
13 open roles · updated today
Get new roles like these by email
One short email each morning with new roles open in your country. Free. Unsubscribe any time.
Trusted by professionals
Iktos integrations
Best Iktos alternatives
Iktos vs. Schrödinger: While both platforms accelerate drug discovery, they represent different core philosophies. Schrödinger is a giant in the field, offering a comprehensive suite of physics-based modeling and machine learning tools for virtual screening and compound optimization. It excels at analyzing and refining existing chemical spaces. Iktos, however, focuses specifically on *de novo* design with its generative AI. Instead of just screening libraries, Iktos creates entirely novel, synthesizable molecules tailored to specific project profiles. This makes Iktos particularly powerful for projects requiring novel chemical matter, whereas Schrödinger provides a broader, more established computational chemistry ecosystem.
Is Iktos worth it?
Why Pharmaceutical & Biotech choose this tool
Key Use Cases
Frequently asked questions
Does Iktos offer a free trial?
What is the best use for Iktos in Pharmaceutical R&D?
Does Iktos integrate with existing R&D platforms?
How does Iktos provide value for money?
Iktos pricing and plans
Prices and features are updated regularly but can change at any time — always confirm on the official website. Some links on this page are affiliate links.
Top 10 AI tools in this category
Take it with you
- What is *de novo* design?
- Iktos vs. Traditional Screening
- Defining the Target Product Profile (TPP)
- Inputting Known Data & Constraints
- Configuring the AI Model
Get Iktos deal alerts
Be the first to know when Iktos drops a new discount, adds features, or changes pricing.
More on AI for Pharmaceutical & Biotech
- Predicting Protein Structures in Minutes: A New Era for Pharma Researchers
- Telehealth Access Trends: What Pharma Professionals Need to Know
- Leqembi’s Sales Forecast Signals New Diagnostic Frontiers for Pharma Professionals
- Roche’s ctDNA Approval: A New Era for Pharma Professionals
- Best AI for Pharma in 2026: Drug Discovery Tools Compared
Latest AI news



About Iktos
Full Description
Iktos is a generative AI platform designed to accelerate early-stage drug discovery. It creates novel, synthesizable small molecules optimized against complex pharmacological properties. This empowers medicinal chemists to move beyond virtual screening and address stringent Target Product Profile constraints for high-quality lead candidates.
Schrödinger
Insilico Medicine
Blank Bio
Recursion

